Name

BEMP

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for BEMP

Name

Alternate Names

Ametycine
Mito-Medac
Mitocin
Mitocin-C
MitoExtra
Mitomycin-C
Mitomycin-X
Mutamycin
Mutamycine

Abbreviations

MITC
Mito
MITO-C
MMC
MTC

Category

Chemotherapy

Subcategory

Alkylating agent
Antibiotic

NSC Number

26980
026980

Primary Site

Breast
Cervical cancer
Gastric cancer
Head and Neck (in combination with radiation therapy)
Non-small cell lung cancer (NSCLC)
Pancreatic cancer
Superficial bladder cancer

Histology

None

Remarks

FDA approved for treatmen of many cancers.

Coding

This drug should be coded

Name

Alternate Names

Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum

Abbreviations

CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP

Category

Chemotherapy

Subcategory

Alkylating agent
Platinum analog

NSC Number

119875

Primary Site

Bladder
ovarian
testicular cancer

Histology

None

Remarks

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

Coding

This drug should be coded

Name

Alternate Names

Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo

Abbreviations

BLE
BLEO
BLM

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

125066

Primary Site

Squamous cell cancers

Histology

None

Remarks

FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

Compound 112531
Eldesine
Eldisine
Lilly 99094
LY-099094
Vincaleukoblastine
Vindesine sulfate

Abbreviations

DAVA
DVA

Category

Chemotherapy

Subcategory

Plant alkyloid

NSC Number

245467

Primary Site

None

Histology

None

Remarks

Vindesine has activity in a wide variety of malignancies including colorectal, lung, breast, and esophageal carcinomas; it also has activity in lymphomas and leukemias, glioma, and melanoma. Neurotoxicity (dose-limiting and cumulative) and cross-resistance with vincristine have limited the usefulness of this agent. Although vindesine in combination with cisplatin is one of the most active regimens for non-small cell lung cancer.

Coding

This drug should be coded
Glossary